SAN DIEGO, June 20, 2024 /PRNewswire/ -- ZMI Pharma, Inc. today announced that it has finalized the acquisition of all strategic assets necessary to manufacture ZIMHI™, including all patents, inventory, automated assembly systems, and the services of two members of the legacy management team. The business was purchased in its entirety as part of a section 363 sale in the Federal Bankruptcy court. Further, it announced that it has entered into an agreement with pharmaceutical distributor FFF Enterprises to act as the exclusive distributor of ZIMHI™. ZMI Pharma, Inc. is the manufacturer of record for the product.
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI®...
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
SAN DIEGO, Oct. 20, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board...